Circulation Journal Official Journal of the Japanese Circulation Society http://www. j-circ.or.jp he N-terminal (1-619 amino acid) and central (2,000-2,500 amino acid) domains of the ryanodine receptors (skeletal: RyR1, cardiac: RyR2) harbor many mutations associated with malignant hyperthermia (MH), catecholaminergic polymorphic ventricular tachycardia (CPVT), and arrhythmogenic right ventricular cardiomyopathy type 2. 1 There is strong evidence to suggest that the interdomain interaction between these regions plays an important role in the mechanism of channel regulation. 2- 16 We reported that dantrolene, a specific agent for the treatment of MH, prevented abnormal Ca 2+ leak by correction of the defective inter-domain interaction between the N-terminal and central domains within MH RyR1 (i.e., aberrant formation of a channel-activating unzipped configuration of the N-terminal/central domain pair in an otherwise resting state). 9 We further showed that, in failing hearts, dantrolene corrected the defective inter-domain interaction within the RyR2, thereby inhibiting Ca 2+ leak through RyR2. 11 More recently, by using the knock-in (KI) mouse model with a human CPVT-associated RyR2 mutation (R2474S), we clarified that a single amino acid mutation within the RyR2 sensitizes the RyR2 channel to activation by luminal [Ca 2+ ] (i.e., a decreased threshold of luminal [Ca 2+ ] for channel activation), and in turn induces spontaneous Ca 2+ sparks and DAD, leading to CPVT, and that danrrolene stabilized the leaky RyR2 by correcting the defective inter-domain interaction. 13 Here, we investigated the in vivo anti-arrhythmic effect of dantrolene in the KI mice model. Background: Dantrolene, a specific agent for the treatment of malignant hyperthermia, was found to inhibit Ca 2+ leak through not only the skeletal ryanodine receptor (RyR1), but also the cardiac ryanodine receptor (RyR2) by correcting the defective inter-domain interaction between N-terminal (1-619 amino acid) and central (2,000-2,500 amino acid) domains of RyRs. Here, the in vivo anti-arrhythmic effect of dantrolene in a human catecholaminergic polymorphic ventricular tachycardia (CPVT)-associated RyR2 R2474S/+ knock-in (KI) mouse model was investigated.
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Methods

ECG Telemetry
ECG was monitored in R2474S/+ KI mice (n=6) and wildtype (WT) mice (n=6) in a conscious state by using ECG telemetry, as previously described, 13 with slight modification. Briefly, transmitters (Data Sciences International, St. Paul, MN, USA) were implanted in the back space with s.c. electrodes in a lead II configuration. Telemetry was recorded after 96 h of recovery from surgery in a conscious state at baseline and after the injection of epinephrine (1 mg/kg of body weight, i.p.) for measurement of the number of VT episodes for 30 min. A subset of telemetered KI (n=6) and WT mice (n=6) were injected with epinephrine (1 mg/kg of body weight, i.p.) and monitored for 30 min. Another set of KI (n=6) and WT mice (n=6) were exercised on a treadmill (Panlab, Barcelona, Spain). After recording the ECG before treatment with dantrolene, these KI mice were treated with dantrolene i.p. (20 mg/kg) for 7-10 days before being exposed to an epinephrine injection or exercise on a treadmill. The QT interval was measured from the beginning of the QRS complex to the end of the T wave based on the 5-min stable ECG segments of sinus rhythm, as previously described. 17 Then, the QT interval was rate-corrected using Bazett's formula (QT interval divided by the square root of the heart rate) and expressed as QTc in the present study. Arrhythmias were defined as follows: non-sustained ventricular tachycardia (VT) was defined as a series of 4-10 consecutive repetitive ventricular ectopic beats (VEBs), and sustained VT (SVT) was defined as a run of >10 consecutive VEBs. 18 
Isolation of Cardiac Cardiomyocytes
The enzymatic isolation of mice cardiomyocytes was performed as described previously. 13 In brief, R2474S/+ KI and WT mice (2-3 months old) were anesthetized with pentobarbital sodium (70 mg/kg of body weight, i.p.), intubated and ventilated with ambient air. An incision in the chest was made, and the heart was quickly removed and retrogradely perfused with a collagenase-free buffer via the aorta under constant flow. The LV myocardium was minced with scissors in a fresh collagenase-containing buffer and the rodshaped adult mice cardiomyocytes were prepared by retrograde perfusion of the hearts with 95%O2/5%CO2-bubbled Minimal Essential Medium (Sigma, St Louis, MO, USA) supplemented with 50 μmol/L [Ca 2+ ], 0.5 mg/ml collagenase B, 0.5 mg/ml, collagenase D, and 0.02 mg/ml protease type XIV. The Ca 2+ concentration was then gradually increased to a final concentration of 1 mmol/L by changing the incubation medium (50 μmol/L, 100 μmol/L, 300 μmol/L, 600 μmol/L and then 1 mmol/L).
The isolated mice cardiomyocytes were transferred to laminin-coated glass culture dishes, and incubated for 12 h at 37°C in a 5%CO2/95%O2 atmosphere. Experiments were carried out at room temperature.
Analysis of Local Ca 2+ Release Events With Laser Scanning Confocal Microscopy
Ca 2+ sparks in intact isolated cardiomyocytes were measured by confocal microscopy to examine the effect of dantrolene on the local Ca 2+ release, as previously described. 13, 19 The Ca 2+ sparks were measured using a laser scanning confocal microscope system (LSM-510, Carl Zeiss) equipped with an argon ion laser coupled to an inverted microscope (Axiovert 100, Carl Zeiss) with a Zeiss ×40 oil-immersion Plan-Neofluor objective (numerical aperture, 1.3; excitation at 488 nm; emission >505 nm). Briefly, intact cardiomyocytes were loaded with fluo-4 AM (20 μmol/L; Molecular Probes) for 30 min at room temperature. Line-scan mode was used, where a single cardiomyocyte was scanned repeatedly (520.8 Hz) along a line parallel to the longitudinal axis, avoiding nuclei. To monitor Ca 2+ sparks, cardiomyocytes were stimulated until the Ca 2+ transient reached a steady state, then stimulation was stopped, and Ca 2+ sparks were then recorded during the subsequent ~10 s rest.
Statistical Analysis
A paired or unpaired t-test was used for statistical comparison of the data between 2 different situations. The chi-square test was used to estimate the effectiveness of dantrolene to prevent occurrence of CPVT. Data are expressed as mean ± SD except for the data of Ca 2+ spark frequency. The data of Ca 2+ spark frequency are expressed as mean ± SE. We accepted a P value less than 0.05 as statistically significant.
Results
Table shows the ECG characteristics obtained from WT and KI mice by telemetry. There was no significant difference in baseline parameters of HR, QT interval, and QTc between WT and KI mice. In all KI mice, bi-directional VT was induced after injection of epinephrine or on exercise, but not in WT mice (Table) . In KI mice, pre-treatment with a daily intraperitoneal injection of 20 mg/kg dantrolene (7-10 days) decreased the frequency of premature ventricular contractions at rest, and prevented the inducible VT (Figures 1-3) . In KI (but not WT) mice, pre-treatment with dantrolene significantly increased the total running distance during exercise on a treadmill (Treated; 188.5±77.1 m, vs Untreated; 22.3±9.0 m, P<0.01). In KI cardiomyocytes, Ca 2+ spark frequency (SpF; s -1 • 100 μm -1 : 5.8±0.3, P<0.01) was much more increased after the addition of isoproterenol than in WT cardiomyocytes (SpF: 3.6±0.2) (Figures 4,5) . In KI cardiomyocytes, the SpF was inhibited by 1.0 μmol/L dantrolene (SpF: 3.6±0.5, P<0.01) (Figures 4,5) . 
Anti-Arrhythmic Effect of Dantrolene
Discussion
Catecholaminergic polymorphic VT is regarded as a highly lethal disease and β-blockers can be used as first line treatment of CPVT. Unfortunately, however, the efficacy of β-blockers in CPVT is known to be low. Most of the patients with CPVT require an implantable cardioverter defibrillator, with 50% of implanted patients receiving appropriate shocks during a 2-year follow up. 20 The most important new aspect of the present study is the finding that pre-treatment with dantrolene, a specific agent for MH, prevented CPVT induced by either epinephrine or exercise, and significantly improved exercise tolerance in KI mice. In addition, in confirmation with our previous report using saponin-permeabilized cardiomyocytes that dantrolene inhibited the PKA-phosphorylation-induced aberrant Ca 2+ release, 13 it markedly suppressed the isoproterenol-induced spontaneous Ca 2+ sparks in intact cardiomyocytes as well. The mechanism by which dantrolene prevented CPVT is likely to be attributable to stabilization of the CPVT-associated, mutated RyR2. This notion is based on the following findings, which have been previously noted: (1) in either RyR1 or RyR2, dantrolene specifically binds to the domain with the same amino-acid sequence; Leu 590 -Cys 609 in RyR1 or Leu 600 -Cys 619 in RyR2), 9,11,21,22 and (2) dantrolene corrects the defective inter-domain interaction between N-terminal: 1-619 and central: 2,000-2,500 domains (i.e., domain unzipping to zipping), thereby inhibiting Ca 2+ leak through RyRs. 9,11, 13 More recently, we further demonstrated that in the RyR2 R2474S/+ KI mice, the affinity of calmodulin (CaM) binding to the RyR2 is reduced upon PKA-mediated phosphorylation, which seems to be a critical cause of spontaneous local Ca 2+ release events. 14 As dantrolene restored a normal level of CaM-binding affinity in the PKA-phosphorylated KI hearts, 14 it is suggested that the defective inter-domain interaction between the N-terminal domain and the central domain of the RyR2 is involved in the reduction of the CaM binding affinity.
It is quite advantageous for the clinical use of dantrolene that it showed no appreciable effect on cardiac function in normal hearts, but it substantially improved the contractile function in pacing-induced failing hearts. 11 This beneficial effect is clearly different from other anti-arrhythmic drugs.
The clinical dose of dantrolene for the treatment for MH is less than 7 mg/kg. In the present study, however, we treated KI mice with a relatively high dose of dantrolene (20 mg • kg -1 • day -1 ). This dosage was determined by a titration study that was aimed to find out the minimum dose to achieve complete prevention of sustained VT on exercise. Before we further move on to clinical studies, we should pay great attention to the effective and safety dosage of dantrolene for the treatment of patients with CPVT or heart failure. 
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